A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: August 25, 2010
Last updated: December 21, 2015
Last verified: December 2015
This randomized, single-blind, proof-of-concept study will investigate the protective effects of early treatment with Mircera in participants with chronic kidney disease on renal disease progression. Participants will be randomly assigned to receive 30 microgram (mcg) Mircera as subcutaneous injection once monthly or matching placebo. Depending on change of hemoglobin values, the dose of Mircera can be adjusted to 50 mcg or 75 mcg once monthly. The anticipated time on study treatment is 24 months.

Condition Intervention Phase
Kidney Disease, Chronic
Drug: Methoxy polyethylene glycol-epoetin beta
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Randomized Controlled, Single-blind, Proof-of-concept-study to Investigate the Protective Effects of Early Treatment With C.E.R.A. in Patients With Chronic Kidney Disease on Renal Disease Progression (PRIMAVERA-Study)

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) [ Time Frame: Baseline, 24 months ] [ Designated as safety issue: No ]
  • Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Change From Baseline in Serum Creatinine Concentration [ Time Frame: Baseline, 24 months ] [ Designated as safety issue: No ]
  • Change From Baseline in Serum Cystatin C Concentration [ Time Frame: Baseline, 24 months ] [ Designated as safety issue: No ]

Enrollment: 241
Study Start Date: September 2010
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mircera Drug: Methoxy polyethylene glycol-epoetin beta
Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
Other Name: Mircera, C.E.R.A.
Placebo Comparator: Placebo Drug: Placebo
Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • For diabetic participants: Type 2 diabetes mellitus with glycated hemoglobin (HbA1c) greater than (>) 7% or anti-diabetic treatment
  • For renal allograft recipients: Status at least 6 months post transplantation
  • Chronic kidney disease stage III
  • Urinary albumin-to-creatinine ratio less than (<) 3000 milligram (mg)/gram (g) or total protein <3000 mg/ 24 hour urine sample where applicable

Exclusion Criteria:

  • Hemoglobin-level < 11 or > 14 g/deciliter (dL)
  • Average systolic blood pressure (SBP) > 140 millimeter of mercury (mm Hg) or average diastolic blood pressure (DBP) > 90 mm Hg
  • Initiation of angiotensin converting enzyme inhibitor, angiotensin 2 receptor blocker or aliskiren treatment less than 3 months before enrolment
  • Present and known iron deficiency
  • HbA1c >9%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01194154

Aachen, Germany, 52057
Augsburg, Germany, 86157
Bad König, Germany, 64732
Berlin, Germany, 10117
Berlin, Germany, 12203
Berlin, Germany, 12435
Bovenden, Germany, 37120
Dresden, Germany, 01307
Düsseldorf, Germany, 40210
Essen, Germany, 45122
Frankfurt, Germany, 60596
Heidelberg, Germany, 69120
Heilbronn, Germany, 74076
Hilden, Germany, 40724
Homburg/Saar, Germany, 66424
Hoyerswerda, Germany, 02977
Kaiserslautern, Germany, 67655
Kiel, Germany, 24106
Köln, Germany, 51109
Lübeck, Germany, 23562
Mannheim, Germany, 68309
Mettmann, Germany, 40822
Muenchen, Germany, 80336
München, Germany, 81377
München-Bogenhausen, Germany, 81925
Münster, Germany, 48149
Neckarsulm, Germany, 74172
Neunkirchen/Saar, Germany, 66538
Saarlouis, Germany, 66740
Ulm, Germany, 89077
Velbert, Germany, 42549
Villingen-Schwenningen, Germany, 78052
Wiesbaden, Germany, 65191
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01194154     History of Changes
Other Study ID Numbers: ML22916  2009-015114-22 
Study First Received: August 25, 2010
Last Updated: December 21, 2015
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Chronic Disease
Kidney Diseases
Renal Insufficiency, Chronic
Disease Attributes
Pathologic Processes
Renal Insufficiency
Urologic Diseases

ClinicalTrials.gov processed this record on May 26, 2016